FDA Approves Feraheme to Treat Iron Deficiency Anemia in Adult Chronic Kidney Disease Patients

Product launch expected in the second half of July 2009
LEXINGTON, Mass.--(Business Wire)--
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and
Drug Administration (FDA) has granted marketing approval for Feraheme
(ferumoxytol) Injection for intravenous (IV) use as an iron replacement therapy
for the treatment of iron deficiency anemia in adult patients with chronic
kidney disease. The recommended dose of Feraheme is an initial 510 mg IV
injection followed by a second 510 mg IV injection three to eight days later.
Feraheme should be administered as an undiluted IV injection delivered at a rate
of up to 1 mL/sec (30 mg/sec). The recommended Feraheme dose may be
readministered to patients with persistent or recurrent iron deficiency anemia.

Feraheme is expected to be commercially available in the U.S. during the second
half of July 2009. Feraheme will be distributed primarily through wholesalers
and specialty distributors. The Company will market and sell Feraheme through
its commercial organization consisting of approximately 150 seasoned
professionals, including an 80-person specialized sales force, an experienced
account management and reimbursement team, and a contract nurse team.

"Feraheme offers patients across the continuum of chronic kidney disease,
including patients not on dialysis and patients on dialysis, a new paradigm for
the treatment of iron deficiency anemia," commented Brian J.G. Pereira, MD,
President and Chief Executive Officer of AMAG. "We are extremely pleased with
the FDA`s approval of Feraheme, and we are well prepared and excited to bring
this new treatment option to patients and physicians."

"Iron deficiency anemia is a significant problem in patients with chronic kidney
disease and is frequently underdiagnosed and undertreated,1,2" said Bryan
Becker, MD, President of the National Kidney Foundation. "We welcome the
availability of a new therapy option for chronic kidney disease patients
affected by iron deficiency anemia."

Clinical Data

Feraheme has been proven to be a safe and effective therapy for treating iron
deficiency anemia in adult chronic kidney disease patients. The FDA approval of
Feraheme was based on safety and efficacy results from four Phase III studies of
patients with chronic kidney disease and iron deficiency anemia. These studies
consisted of three open-label, multi-center, randomized safety and efficacy
clinical studies and a fourth double-blind, multi-center, randomized,
placebo-controlled cross-over safety study. Each of the three pivotal safety and
efficacy studies achieved statistical significance in its primary endpoint: the
mean change in hemoglobin from baseline at Day 35 after the first dose. Feraheme
significantly increased hemoglobin levels as compared to oral iron across the
spectrum of chronic kidney disease. Overall, 1,726 subjects were exposed to
Feraheme in the development program, including 1,562 patients with all stages of
chronic kidney disease.

In accordance with the Pediatric Research Equity Act (PREA) requirement, the
Company will conduct two post-marketing studies in the pediatric chronic kidney
disease population; one in patients on dialysis and the other in patients not on
dialysis. Each study will enroll approximately 75 subjects, collecting
pharmacokinetic, safety and efficacy data as compared to oral iron. The Company
expects to commence these studies in 2010.

Important Safety Information

Feraheme is indicated for the treatment of iron deficiency anemia in adult
patients with chronic kidney disease. Feraheme is contraindicated in patients
with evidence of iron overload, known hypersensitivity to Feraheme or any of its
components, and patients with anemia not caused by iron deficiency.

In clinical studies, hypotension was reported in 1.9% (33/1,726) of subjects
receiving Feraheme, including three patients with serious hypotensive reactions.
Adverse reactions potentially associated with hypersensitivity (e.g., pruritus,
rash, urticaria or wheezing) were reported in 3.7% (63/1,726) of these subjects
including 0.2% (3/1,726) with serious hypersensitivity reactions. Patients
should be observed for signs and symptoms of hypersensitivity for at least 30
minutes following Feraheme injection and the drug should only be administered
when treatment of hypersensitivity reactions is readily available. Excessive
therapy with parenteral iron can lead to excess storage of iron with the
possibility of iatrogenic hemosiderosis. Patients should be regularly monitored
for hematologic response during parenteral iron therapy, noting that lab assays
may overestimate serum iron and transferrin bound iron values in the 24 hours
following administration of Feraheme. As a superparamagnetic iron oxide,
Feraheme may transiently affect magnetic resonance diagnostic imaging studies
for up to 3 months following the last Feraheme dose. Feraheme will not affect
X-ray, computed tomography (CT), positron emission tomography (PET), single
photon emission computed tomography (SPECT), ultrasound, or nuclear imaging.

In clinical trials, the most commonly occurring adverse reactions in Feraheme
treated patients versus oral iron treated patients reported in ≥ 2% of chronic
kidney disease patients were diarrhea (4.0% vs. 8.2%), nausea (3.1% vs. 7.5%),
dizziness (2.6% vs. 1.8%), hypotension (2.5% vs. 0.4%), constipation (2.1% vs.
5.7%) and peripheral edema (2.0% vs. 3.2%). In clinical trials, adverse
reactions leading to treatment discontinuation and occurring in 2 or more
Feraheme-treated patients included hypotension, infusion site swelling,
increased serum ferritin level, chest pain, diarrhea, dizziness, ecchymosis,
pruritus, chronic renal failure, and urticaria.

Click here to view Feraheme`s product insert which is also available on our
website at www.amagpharma.com.

Conference Call and Webcast Access

AMAG Pharmaceuticals, Inc. will host a webcast and conference call tomorrow at
8:30 a.m. ET to discuss today`s announcement.

To access the conference call via telephone, please dial (877) 412-6083 from the
U.S. or (702) 495-1202 for international callers. A telephone replay will be
available from approximately 11:30 a.m. ET on July 1, 2009 through midnight July
3, 2009. To access a replay of the conference call, dial (800) 642-1687 from the
U.S. or (706) 645-9291 for international access. The passcode for the live call
and the replay is 18122806.

An audio webcast of the call will be available through the Investors section of
the Company`s website at www.amagpharma.com. A replay of the webcast will also
be available from approximately 10:30 a.m. ET on July 1, 2009, through midnight
July 31, 2009.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its
proprietary technology for the development and commercialization of a
therapeutic iron compound to treat iron deficiency anemia and novel imaging
agents to aid in the diagnosis of cancer and cardiovascular disease. For
additional company and product information please visit www.amagpharma.com.

Feraheme was developed by the Company and is composed of superparamagnetic iron
oxide particles with a proprietary semi-synthetic carbohydrate coating.

Feraheme is a trademark of AMAG Pharmaceuticals, Inc.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and other federal securities
laws. Any statements contained herein which do not describe historical facts,
including but not limited to, statements regarding our anticipated Feraheme
availability and launch timing, and our post marketing pediatric studies and the
timing thereof, are forward looking statements which involve risks and
uncertainties that could cause actual results to differ materially from those
discussed in such forward looking statements. Such risks and uncertainties
include: (1) uncertainties regarding our ability to manufacture Feraheme, (2)
the fact that we have limited sales and marketing expertise, (3) uncertainties
regarding our ability to successfully compete in the intravenous iron
replacement market, (4) uncertainties regarding our ability to obtain favorable
coverage, pricing and reimbursement for Feraheme, if approved, (5) uncertainties
relating to our patents and proprietary rights, and (6) other risks identified
in our Securities and Exchange Commission filings, including our Annual Report
on Form 10-K for the fiscal year ended December 31, 2008. We caution you not to
place undue reliance on any forward-looking statements, which speak only as of
the date they are made. We disclaim any obligation to publicly update or revise
any such statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from those set forth
in the forward-looking statements.

1 Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney
disease in the National Health and Nutritional Examination Survey 1988-2004.
Clin J Am Soc Nephrol. 2009 Jan;4(1):57-61.

2 Curtis BM, Barrett BJ, Djurdjev O, Singer J, Levin A. Evaluation and treatment
of CKD patients before and at their first nephrologist encounter in Canada. Am J
Kidney Dis. 2007 Nov;50(5):733-42

AMAG Pharmaceuticals, Inc.
Kristen Galfetti, 617-498-3362
or
Carol Miceli, 617-498-3361

Copyright Business Wire 2009